US/UK/Canada

Share

About Us

Curasight is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology provides improved diagnosis and treatment in multiple cancer types, most notably for brain and prostate cancer.

Pick a time period -
Tags ( Active)

Curasight announces international patent application for uTREAT® to broaden IP protection

· New patent application related to uTREAT will extend patent protection until 2043 · Application adds several new alpha- and beta-emitters to protection under existing issued patents · Application strengthens patent family for Curasight’s uPAR-targetting technology, aimed at improving cancer diagnosis (uTRACE) and treatment (uTREAT) Copenhagen, Denmark, 13 November 2024 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) announces today the publication of its international patent application for uTREAT®. The patent application is in addition to already granted patents

Curasight will present at the BioStock Life Science Summit, November 21

The seventh edition of the BioStock Life Science Summit will take place in Lund on November 20-21. CSO Andreas Kjaer will present Curasight to industry leaders, specialist investors and potential partners.The Summit connects innovation and capital, providing small-to-medium size Nordic companies from a wide range of therapeutic areas the platform and opportunity to make their case to both Swedish and international investors as well as top-level potential partners in a unique boutique setting.    Date: November 21 Time: 14:05 Location: Auditorium at Medicon Village, Lund Read

Curasight announces brain cancer as first indication for uTREAT[®]: First patient to be dosed Q2 2025

· Brain cancer (high-grade glioma (HGG)) selected as first indication for uTREAT[®] · Addresses a clear unmet medical need · Clinical development plan established · Clinical trial application (CTA) submission anticipated early Q1 2025 · First patient dosed with uTREAT late Q2 2025 Copenhagen, Denmark, 11 November 2024 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) announces today that it has chosen brain cancer (high-grade glioma (HGG)) as the first indication for uTREAT[®] as a potential cancer therapeutic. The company aims to dose the first patient with uTREAT[

BioStock: Full phase II results of uPAR-PET in glioblastoma published

Curasight has published the full data from an investigator-initiated phase II trial evaluating its uTRACE imaging technology in brain cancer patients in the peer-reviewed journal EJNMMI Research. The results – which were first reported in connection with an oral presentation at a conference last year – supports the strategy to develop uTRACE and the therapeutic uTREAT in parallel.Read the full article at biostock.se: https://www.biostock.se/en/2024/11/full-phase-ii-results-of-upar-pet-in-glioblastoma-published/ This is a press release from BioStock - Connecting Innovation & Capital.

Curasight to present at Dansk Aktionærforening InvestorDagen

Copenhagen, Denmark, 8 November 2024 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces that CEO Ulrich Krasilnikoff and CMO Andreas Kjær have been invited to present the company’s latest progress and strategy at Dansk Aktionærforening InvestorDagen in Copenhagen 11 November 2024Management will give an overall update on the company’s pipeline based on the proprietary uPAR theranostics platform and focused on diagnosing and treating cancer, and its view on the newly published peer-reviewed data in the journal EJNMMI Research from the Phase II uTRACE trial in

Clinical phase II trial of uPAR-PET in brain cancer patients published; data supports development of uTREAT for brain cancer

· Curasight’s radiopharmaceutical approach leverages the uPAR theranostic platform with the aim of providing improved diagnosis (uTRACE) and more gentle treatment (uTREAT) of certain types of cancers · Data from the Phase II uTRACE trial is now published in full in the peer-reviewed journal EJNMMI Research Copenhagen, Denmark, 7 November 2024 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) announces today that the investigator-initiated phase II study using uPAR-PET in brain cancer has been publishedThe investigator-initiated clinical trial testing [68]Ga-NOTA-AE105

BioStock: Curasight well-placed in hot radiopharma sector

The radiopharmaceutical sector is gaining considerable momentum as companies increasingly recognize its potential to offer highly targeted cancer treatments. This has led to a surge in investments, acquisitions, and partnerships, positioning radiopharmacy as one of the hottest areas in oncology. Curasight, a Danish clinical-stage biotech company specializing in innovative precision radionuclide diagnostics and therapy, is well-placed to benefit from this growth.Read the full article at biostock.se: https://www.biostock.se/en/2024/10/curasight-well-placed-in-hot-radiopharma-sector/

Curasight A/S announces last day of trading in BTU and first day of trading in warrant series TO2 and TO3

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL REGISTRATION OR OTHER MEASURES BEYOND WHAT IS REQUIRED UNDER DANISH LAW. Copenhagen, Denmark, 11 October 2024 – Curasight A/S’s (“Curasight” or the “Company”) rights issue of units, with a subscription period that ended on 30 September

Curasight A/S rights issue heavily oversubscribed

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM DANISH LAW. SEE THE “IMPORTANT INFORMATION” SECTION AT THE END OF THIS PRESS RELEASE. Copenhagen, Denmark, 3 October 2024 – The subscription period in Curasight A/S (“Curasight” or the “Company” – TICKER: CURAS) preferential rights

Commencement of subscription period in Curasight’s preferential rights issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM DANISH LAW. SEE THE “IMPORTANT INFORMATION” SECTION AT THE END OF THIS PRESS RELEASE. Copenhagen, Denmark, 16 September 2024 – The subscription period in Curasight A/S ("Curasight" or the “Company" – TICKER: CURAS) rights issue of

Curasight A/S publishes prospectus due to upcoming rights issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM DANISH LAW. SEE THE “IMPORTANT INFORMATION” SECTION AT THE END OF THIS PRESS RELEASE. Copenhagen, Denmark, 12 September 2024 – Curasight A/S ("Curasight" or the “Company" – TICKER: CURAS) announced on 4 September 2024 that the Board

BioStock: Curasight carries out the first step of capitalization

In late June, Curasight announced a capital raise package of up to DKK 120 million to finance the ongoing development of its theranostic platform. Investment firm Fenja Capital II is honoring its pre-subscription obligations by subscribing for approximately a third of the units offered through the two unit issues. The total capitalization will fund important inflection points within the coming year.Read the full article at biostock.se: https://www.biostock.se/en/2024/09/curasight-carries-out-the-first-step-of-capitalization/ This is a press release from BioStock - Connecting

The Board of Directors resolves on a directed issue of units and preferential rights issue of units

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM DANISH LAW. SEE THE “IMPORTANT INFORMATION” SECTION AT THE END OF THIS PRESS RELEASE. Copenhagen, Denmark, 4 September 2024 – Curasight A/S ("Curasight" or the “Company" – TICKER: CURAS) today announces that the Board of Directors

BioStock: Curasight targets clinical proof-of-concept for uTREAT

Having secured financing for the ongoing clinical development of uTRACE, Curasight can now enter the next level in developing the therapeutic side of its theranostic approach. This will be done by rapidly achieving proof-of-concept in a single indication with uTREAT. BioStock contacted CEO Ulrich Krasilnikoff in conjunction with the Q2 report to learn more.Read the full article at biostock.se: https://www.biostock.se/en/2024/08/curasight-targets-clinical-proof-of-concept-for-utreat/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Interim report Q2 2024

Business Highlights during the second quarter 2024 · Strengthened financial base with funding of DKK 27.8 million and potential of up to DKK 120 million in total. · Clinical trial application accepted by the European Medicines Agency (EMA) for the investigation of uTRACE[®] in a phase 2 trial in prostate cancer. · Second milestone payment received under the agreement with Curium Inc. using uTRACE[®] for the improved diagnosis in prostate cancer. USD 0.5 million was triggered following enrollment of the first patient in the phase 2 trial in prostate cancer. · Plans proceeding to

Curasight issues warrants as part of long-term incentive program

Copenhagen, Denmark, 30 July 2024 - Curasight A / S ("Curasight" or the “Company"- TICKER: CURAS) announces today that it has re-issued a total of 59,132 warrants as part of the Company’s existing long-term incentive program covering the Company’s Board of Directors, Executive Management and other key employees.As part of the Company’s existing long-term incentive programs, the Board of Directors has today resolved to re-issue a total of 59,132 (previously lapsed) warrants with rights to subscribe for a total of DKK 2,956.60 nominally worth of shares in the Company. The re-issuance of

Resolutions of the Extraordinary General Meeting of Curasight A/S on 2 July 2024

Copenhagen, Denmark, 2 July 2024 – today Curasight A/S ("Curasight" or the “Company" – TICKER: CURAS) held an Extraordinary General Meeting at the office of DLA Piper Denmark, Oslo Plads 2, 2100 Copenhagen OE, DenmarkToday, the shareholders in Curasight passed the following resolutions at an Extraordinary General Meeting in accordance with the agenda: 1. Proposals from the Board of Directors 1.1 Authorisation to the Board of Directors to issue warrants with pre-emption   rights A proposal from the Board of Directors to introduce a warrant authorization to the Board of Directors in

Directed issues registered at the Danish Business Authority

Copenhagen, Denmark, 01 July 2024 - Curasight A/S ("Curasight" or the “Company" – TICKER: CURAS) today announces that the directed issues decided by the Board of Directors and announced on the 14[th] of June 2024 are now registered at the Danish Business Authority. The directed issues increase the Company's number of shares from 19,893,891 to a total of 20,682,427 shares. The Company's share capital will increase from DKK 994,694.55 to a total of DKK 1,034,121.35. The new shares are expected to be in the subscribers’ accounts around the 4 of July 2024.Advisors Sedermera Corporate Finance

BioStock: Curasight CEO comments on capital raise and milestone

Curasight has enrolled the first patient in its phase II trial with uTRACE in prostate cancer, activating a second USD 500,000 payment from partner Curium. Curasight also announced a capital raise aimed at further strengthening the company’s finances. The fund raise, which includes a directed share issue, a loan facility, and warrants will initially provide DKK 27.8 million, and the package could eventually provide up to DKK 120 million.Read the full article at biostock.se: https://www.biostock.se/en/2024/06/curasight-ceo-comments-on-capital-raise-and-milestone/ This is a press

Curasight to present at HC Andersen Capital

Copenhagen, Denmark, 22 June 2024 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces that CEO Ulrich Krasilnikoff and CSO professor Andreas Kjær will present the new capitalization and funding of the company at HC Andersen Capital 25 June 2024.The transaction announced on 14 June 2024 provides potential new funding up to DKK 120 million. Full financing will extend the cash runway well into the second half of 2025. The funding ensures strategic flexibility and supports the continued pipeline development. In terms of the pipeline, Curasight has just enrolled the

Notice of Extraordinary General Meeting

The Board of Directors is pleased to invite shareholders of Curasight A/S (“Curasight” or the “Company”) to an Extraordinary General Meeting on Tuesday 2 July 2024 at 10:00 AM (CET) at the office of DLA Piper Denmark, Oslo Plads 2, 2100 Copenhagen OE, Denmark.Agenda 1. Proposals from the Board of Directors 1. 1.1 Authorisation to the Board of Directors to issue warrants with pre-emption rights 2. 1.2 Authorisation to the Board of Directors to issue warrants without pre-emption rights 3. 1.3 Authorisation to the chairman of the meeting Complete proposals 1. Proposals

Curasight A/S resolves on directed issues and a loan facility

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM DANISH LAW. SEE THE “IMPORTANT INFORMATION” SECTION AT THE END OF THIS PRESS RELEASE. Copenhagen, Denmark, 14 June 2024 - Curasight A/S ("Curasight" or the “Company" – TICKER: CURAS) today announces that the Board of Directors has

Curasight Announces Enrollment of First Patient in Phase 2 trial with uTRACE[®] in Prostate Cancer

· Recruitment of first patient triggers second milestone payment of USD 500.000 to Curasight under the collaboration agreement for uTRACE[®] in prostate cancer with Curium Inc. · Milestone is an important step in the development of the uTRACE PET imaging technology, part of Curasight’s theranostic platform leveraging the uPAR target for improved diagnosis (uTRACE[®]) and radioligand treatment (uTREAT[®]) of certain cancers · Under the agreement signed with Curium Inc. in 2023, Curasight is eligible to receive up to mUSD 70 in development and commercial milestones plus double-digit

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe